Quantcast

Latest Eisai Co. Ltd. Stories

2011-12-15 00:20:01

Tokyo, Dec 15, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited (Eisai Canada) has received approval from Health Canada for Halaven (eribulin mesylate), a novel anticancer agent discovered and developed by Eisai, for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an...

2011-12-13 04:20:01

Tokyo, Dec 13, 2011 - (JCN Newswire) - Eisai Co. Ltd today submitted a marketing and manufacturing authorization application to Japan's Ministry of Health, Labour and Welfare seeking approval of a new dry syrup formulation of its Alzheimer's disease (AD) treatment Aricept (donepezil hydrochloride).In August 2007, the indication of Aricept was expanded to include severe AD. The simultaneous approval of additional dosage, which states that once daily dosage of donepezil hydrochloride may be...

2011-12-02 00:20:01

Aims to Provide Personalized Medicine by Integrating Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics Tokyo, Dec 2, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that the company's U.S. research subsidiary H3 Biomedicine held a ceremony on December 1 (U.S. Eastern Standard Time) in Massachusetts, Cambridge, to mark the official opening and commencement of operations of its new research facility. H3 Biomedicine aims to...

2011-12-01 00:20:01

Tokyo, Dec 1, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited held a ceremony on November 30 (local time in Toronto) to celebrate its official opening and entry into the Canadian healthcare marketplace.Eisai Canada was established in Mississauga, Ontario, one of largest biopharmaceutical clusters and medical communities in North America, in April 2010 as Eisai's first pharmaceutical sales base for the Canadian market....

2011-11-30 00:20:01

Tokyo, Nov 30, 2011 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch Warfarin Granules 0.2%, a new formulation of the company's oral anti-coagulant Warfarin (warfarin potassium), on December 1 in Japan.Warfarin Granules 0.2% received marketing authorization in Japan on July 15 of this year and was subsequently listed on Japan's National Health Insurance (NHI) drug price list on November 28. This new formulation is designed to help patients who find it difficult to...

2011-11-18 00:20:01

Tokyo, Nov 18, 2011 - (JCN Newswire) - Eisai Co. Ltd announced today that it has entered into a Japan co-promotion agreement with Novartis Pharma K.K. for three Novartis Pharma therapies for chronic obstructive pulmonary disease (COPD). These include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate), which were launched in Japan on September 20, 2011, and, if approved, the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate...

2011-09-28 08:20:01

Tokyo, Sept 28, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they will launch Humira(R) (adalimumab) Prefilled Syringe 20mg/0.4mL, a fully human anti-TNF-α monoclonal antibody for the treatment of polyarticular juvenile idiopathic arthritis (JIA) patients with low body weight, on September 29.Humira Prefilled Syringe 20mg/0.4mL received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare on July 1 of this...

2011-09-26 04:20:01

Tokyo, Sept 26, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have submitted an application in Japan seeking approval of inhibition of structural damage of joints in rheumatoid arthritis as an additional indication for Humira(R) (adalimumab; recombinant) Pre-filled Syringe 40 mg/0.8 mL, a fully human anti-TNF-alpha monoclonal antibody jointly developed by the two companies.The submission is based on the results of a double-blind study (HOPEFUL1...

2011-09-07 20:20:01

Enters Collaborative Development Agreement with SFJ Pharmaceuticals for Anticancer Agent E7080 (lenvatinib) Tokyo, Sept 7, 2011 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a collaborative development agreement with SFJ Pharma Ltd. ("SFJ"), a wholly-owned subsidiary of SFJ Pharmaceuticals, LP., II (California), in an effort to further accelerate the late-stage clinical development of its new drug pipeline by effectively leveraging...

2011-09-01 04:20:02

Looks to Expand Global Epilepsy Product Portfolio Tokyo, Sept 1, 2011 - (JCN Newswire) - Eisai Co., Ltd. announced today that 35 abstracts highlighting the latest results from studies with its pipeline and portfolio products (perampanel: 5 abstracts, Zonegran(R): 5 abstracts, Zebinix(R): 25 abstracts) were presented at the 29th International Epilepsy Congress which took place in Italy (Rome) between August 28 and September 1, 2011. This research demonstrates...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related